IgG4-related disease: advances in pathophysiology and treatment. (4th May 2023)

• Record Type: Journal Article
• Authors: Peyronel, Francesco; Fenaroli, Paride; Maritati, Federica; Schleinitz, Nicolas; Vaglio, Augusto
• Is Part Of: Expert review of clinical immunology. Volume 19:Number 5(2023)
• Page Start: 537
• Page End: 547
• Publication Date: 2023-05-04
• Subjects: IgG4-related disease -- IgG4 -- fibrosis -- glucocorticoids -- rituximab -- treatment; Clinical immunology -- Periodicals; 616.079
• DOI: 10.1080/1744666X.2023.2195627
• Languages: English
• ISSNs: 1744-666X

Abstract

ABSTRACT: Introduction: IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory disease affecting multiple organs. In recent years basic and translational research has unveiled the role of different cellular subtypes and cytokines in inducing and perpetuating the pathological process, eventually leading to fibrosis of affected tissues. Hopefully, the growing knowledge of the disease pathogenesis will lead to patient-tailored treatments in the near future. Areas covered: This review focuses on the most recent discoveries concerning the pathogenic mechanisms underlying IgG4-RD and highlights their potential role as specific therapeutic targets. Expert opinion: IgG4-RD is a systemic and multifaceted disease. Its sensitivity to glucocorticoids is well known, however new targeted therapies are emerging that can reduce glucocorticoid exposure and achieve sustained clinical responses. Clinicians managing patients with such a rare and heterogeneous disease must therefore be aware of its varied phenotype and traditional and novel therapeutic strategies.